STEADY-STATE SERUM KINETICS OF ZOTEPINE

被引:19
作者
OTANI, K
KONDO, T
KANEKO, S
HIRANO, T
MIHARA, K
FUKUSHIMA, Y
机构
[1] Department of Neuropsychiatry, Hirosaki University Hospital, Hirosaki
关键词
ZOTEPINE; SERUM CONCENTRATION; STEADY-STATE; SMOKING; BENZODIAZEPINE;
D O I
10.1002/hup.470070506
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The steady-state serum kinetics of zotepine, an antipsychotic drug, were studied in 59 psychiatric in-patients receiving 50-500 mg/day (mean 215 mg/day) of the drug. There was a 26-fold inter-individual variation in the concentration/dose ratios (C/D ratios: ng/ml/mg/kg), which ranged from 2.4 to 62.2 (mean 13.2). The smokers (n = 37) had significantly lower C/D ratios (mean +/- SD: 9.7 +/- 7.0 vs 19.0 +/- 15.5, p < 0.01), while the patients co-administered benzodiazepines (n = 14) had significantly higher C/D ratios (19.6 +/- 12.5 vs 11.2 +/- 10.9, p < 0.01) than the others. There was no significant relationship between the C/D ratios and age or gender. In the 24 cases where the dose was fixed at 100 mg/day in the first week and at 200 mg/day for the next 3 weeks, no significant difference was found in the mean C/D ratios during the 4 weeks. The present study thus suggests a large inter-individual variation in the metabolism of zotepine, and that smoking enhances, and co-administration of benzodiazepines inhibits, the metabolism. Age and gender do not affect the kinetics of the drug. The results also suggest no dose-dependent kinetics and no enzyme-inducing effect of the drug.
引用
收藏
页码:331 / 336
页数:6
相关论文
共 27 条
[1]   RELATIONSHIPS BETWEEN DRUG CONCENTRATIONS IN SERUM AND CSF, CLINICAL EFFECTS AND MONOAMINERGIC VARIABLES IN SCHIZOPHRENIC-PATIENTS TREATED WITH SULPIRIDE OR CHLORPROMAZINE [J].
ALFREDSSON, G ;
BJERKENSTEDT, L ;
EDMAN, G ;
HARNRYD, C ;
OXENSTIERNA, G ;
SEDVALL, G ;
WIESEL, FA .
ACTA PSYCHIATRICA SCANDINAVICA, 1984, 69 :49-74
[2]   ZOTEPINE IN THE TREATMENT OF SCHIZOPHRENIC-PATIENTS WITH PREVAILINGLY NEGATIVE SYMPTOMS - A DOUBLE-BLIND TRIAL VS HALOPERIDOL [J].
BARNAS, C ;
STUPPACK, CH ;
MILLER, C ;
HARING, C ;
SPERNERUNTERWEGER, B ;
FLEISCHHACKER, WW .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1992, 7 (01) :23-27
[3]   IMPORTANCE OF GENETIC-FACTORS IN THE REGULATION OF DIAZEPAM METABOLISM - RELATIONSHIP TO S-MEPHENYTOIN, BUT NOT DEBRISOQUIN, HYDROXYLATION PHENOTYPE [J].
BERTILSSON, L ;
HENTHORN, TK ;
SANZ, E ;
TYBRING, G ;
SAWE, J ;
VILLEN, T .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (04) :348-355
[4]   DISPOSITION OF PERPHENAZINE IS RELATED TO POLYMORPHIC DEBRISOQUIN HYDROXYLATION IN HUMAN-BEINGS [J].
DAHLPUUSTINEN, ML ;
LIDEN, A ;
ALM, C ;
NORDIN, C ;
BERTILSSON, L .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 46 (01) :78-81
[5]   TOBACCO SMOKING AND DRUGS - A CLINICALLY IMPORTANT INTERACTION [J].
DARCY, PF .
DRUG INTELLIGENCE & CLINICAL PHARMACY, 1984, 18 (04) :302-307
[6]   FLUPHENAZINE PHARMACOKINETICS AND THERAPEUTIC RESPONSE [J].
DYSKEN, MW ;
JAVAID, JI ;
CHANG, SS ;
SCHAFFER, C ;
SHAHID, A ;
DAVIS, JM .
PSYCHOPHARMACOLOGY, 1981, 73 (03) :205-210
[7]   EFFECTS OF SMOKING ON FLUPHENAZINE CLEARANCE IN PSYCHIATRIC-INPATIENTS [J].
ERESHEFSKY, L ;
JANN, MW ;
SAKLAD, SR ;
DAVIS, CM ;
RICHARDS, AL ;
BURCH, NR .
BIOLOGICAL PSYCHIATRY, 1985, 20 (03) :329-352
[8]  
FLEISCHHACKER WW, 1989, PSYCHOPHARMACOL BULL, V25, P97
[9]   PLASMA CONCENTRATIONS OF PERPHENAZINE AND ITS SULFOXIDE METABOLITE DURING CONTINUOUS ORAL TREATMENT [J].
HANSEN, LB ;
LARSEN, NE .
PSYCHOPHARMACOLOGY, 1977, 53 (02) :127-130
[10]   COMPARATIVE ENZYME-INDUCING EFFECTS OF CHLORPROMAZINE AND FLUPHENAZINE THERAPIES IN PSYCHOTIC-PATIENTS [J].
HARMAN, AW ;
FREWIN, DB ;
PRIESTLY, BG .
PSYCHOPHARMACOLOGY, 1980, 69 (01) :35-37